FDA data Registry peer set 3 peers

Alternatives to umeclidinium

3 same-class SPL records vs umeclidinium - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.

Brand: Incruse Ellipta

Long-Acting Muscarinic Antagonist (LAMA) Prescription 3 alternatives found

About umeclidinium

Incruse Ellipta is a medicine that helps people with COPD breathe easier. It contains umeclidinium, which is a long-acting muscarinic antagonist (LAMA).

Used for: Incruse Ellipta is used to help people with chronic obstructive pulmonary disease (COPD) breathe better. COPD is a long-term lung disease that makes it hard to breathe. This medicine is not for sudden breathing problems or asthma.

3 Long-Acting Muscarinic Antagonist (LAMA) peers (wide set)

Compare umeclidinium vs aclidinium side-by-side →

umeclidinium vs aclidinium & glycopyrrolate · FAERS reaction fields

FAERS top-reaction field "Asthma" shows the widest count spread between umeclidinium and aclidinium, glycopyrrolate, tiotropium in this extract (10,213-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.

Side Effect umeclidinium aclidiniumglycopyrrolatetiotropium
Dyspnoea 1,352 - 1,000 -
Cough 701 655 626 8,611
Asthma 604 814 793 10,817
Wrong Technique In Device Usage Process 520 - - -
Pneumonia 509 692 538 8,380
Chronic Obstructive Pulmonary Disease 403 - 326 -
Fatigue 364 - 352 -
Wheezing 325 645 674 6,761

"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.

umeclidinium peer mix vs class inventory

Peer mix

0 OTC and 3 Rx SPL records in this peer set (3 total). Class inventory for Long-Acting Muscarinic Antagonist (LAMA): 4 drugs.

Frequently Asked Questions

What same-class SPL records sit beside umeclidinium?
This registry lists 3 Long-Acting Muscarinic Antagonist (LAMA) medication records beside umeclidinium, including aclidinium, glycopyrrolate, tiotropium. Grouping is therapeutic-class indexing from openFDA/SPL, not a product recommendation.

Reading a wide Long-Acting Muscarinic Antagonist (LAMA) peer set (3 records)

umeclidinium (Incruse Ellipta) sits in a wide Long-Acting Muscarinic Antagonist (LAMA) peer set (3 of 3 class peers shown). Labeled indication field for umeclidinium: Incruse Ellipta is used to help people with chronic obstructive pulmonary disease (COPD) breathe better.

Top FAERS reaction fields for umeclidinium total 5,414 reports across 10 reactions, set beside aclidinium, glycopyrrolate, tiotropium. Counts are exposure-weighted submissions, not per-patient risk.

Registry note: Therapeutic-class peer lists are registry indexes, not prescribing advice. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.

Full umeclidinium profile →

Field note for umeclidinium: see also the generic vs brand label guide when reading Incruse Ellipta SPL strings.